For licensed medical cannabis operators

Your patients aren't failing your products.
Your onboarding is failing your patients.

The average medical cannabis patient quits within 3–4 months. Every dropout is acquisition cost written off, lifetime value erased, and a de-marketing event broadcast to their GP and social circle. It has a documented fix — measured at 8.5× retention improvement, across 100,000+ patients.

Book the Business Audit Call — $500 90 minutes · Written Retention Assessment same day · No retainer required
Documented Outcome · Clinical Protocol System
4 mo → 34 mo
Average patient retention, before and after clinical onboarding protocol — measured across Israel's largest licensed operators. 8.5× improvement. Same products. Different process.
8.5×
Retention improvement
under clinical protocol
100,000+
Patients through
the system in Israel
MoH
Licensed Medical Cannabis
Instructor since 2008
3 Govts
Advisor: Israel · Czech Republic
· Bulgaria
What This Is Actually Costing You

Patient attrition isn't a product problem.
It's a revenue leak with three names.

Before discussing solutions, quantify the status quo. Every operator knows their dropout rate. Very few have mapped what it actually costs them — on the unit economics, on the brand, and on the regulatory ledger.

Cost 01
The Acquisition Tax
You spend real money acquiring each patient — marketing, intake, prescription coordination, dispensary staff. When that patient quits at month 3, you've collected 3 months of revenue against 12+ months of acquisition and servicing cost. The unit economics only work if patients stay long enough to become profitable. Most don't.
The retention problem is a margin problem. It compounds with every new patient you acquire into a broken onboarding system.
Cost 02
The Word-of-Mouth Damage
A patient who quits at month 3 doesn't say "I needed better guidance." They say "I tried cannabis and it didn't work." That narrative spreads — to their family, their GP, their social circle. Every dropout is an active de-marketing event for your entire product category, not just your brand.
Your least-retained patients are your most vocal critics. Fixing retention fixes reputation.
Cost 03
The Regulatory Exposure
Licensing bodies and health ministries are increasingly tracking patient outcome data — not just production compliance. High dropout rates are a metric regulators will eventually ask you to explain. The operators who can demonstrate sustained patient engagement are the ones building durable licences.
Patient retention data is becoming part of the regulatory conversation. Build it now, before it's required.
The Documented Result

This has already been done.
At scale. With your competitors.
The numbers are on record.

Average Patient Retention · Before / After Clinical Protocol
4 mo
Without protocol
→
34 mo
With clinical onboarding
Measured across Israel's largest licensed operators · 8.5× retention improvement · Same products, different onboarding process
8.5× Retention improvement
with clinical protocol
10,000+ Patients personally
supervised by Gil
100,000+ Total patients through
the system in Israel

From 2008 through the early 2020s, Gil built and ran structured clinical onboarding programmes inside Israel's largest licensed cannabis operators. The programmes did not change the products on the shelf. They changed what happened between prescription and first use — the gap that loses most patients before they ever establish a working protocol.

The mechanism was simple and specific: a calibrated starting dose matched to the patient's condition and history, a written week-by-week titration schedule, and a structured tracking system to distinguish therapeutic effect from side effects. Patients who went through the programme stayed on treatment for an average of 34 months. Those who didn't averaged 4 months before quitting.

This is not a content programme. Not a welcome email sequence. Not a patient portal. It is a clinical onboarding system with a pharmacological basis — built, tested, and validated at scale. The Ministry of Health knows Gil's name. The Knesset heard his testimony. The Czech Republic Parliament changed policy based on his input. The system works because it was built by someone who understood the problem from both sides: as Patient #7 in Israel, and as the licensed instructor who built the country's first patient and nurses education programmes.

Operators · Institutions · Governments
Licensed operators Gil has worked with
Tikun Olam BOL Pharma IMC Siach Bazelet Group Sheifa Lachaim Eybna Technologies YoFuMo USA
Governments & institutions advised
Israel Ministry of Health Knesset — Israeli Parliament Czech Republic Parliament
The Engagement Model

Three phases. One entry point.
You choose how far to go.

The starting point is always the same: a Business Audit Call where Gil diagnoses your specific retention problem and tells you exactly what to do about it. From there, engagement scales in three distinct phases — each optional, each with a clear deliverable.

01
Phase 01 · Patient Rescue
Gil handles your failing patients directly. You refer them. They stay.
The fastest, lowest-risk way to prove the system works on your patient base. You identify patients who are at dropout risk — or have already given up — and refer them to Gil for a personalised Rescue Session. He provides the clinical protocol. They get back on track. You measure the difference in retention before and after.
Typical entry: 10–20 patient referrals · Per-patient pricing or packaged · No staff training required · Results visible within 30–60 days
02
Phase 02 · Team Education
Gil trains your clinical staff to deliver the protocol at intake.
Once Phase 1 demonstrates the retention improvement on your patient base, the next step is building the capability internally. Gil — as a licensed Ministry of Health Medical Cannabis Instructor — runs structured training for your dispensary staff, nurses, and patient-facing team. This is the same curriculum framework that produced the 100,000-patient system, adapted to your specific patient profile and product portfolio.
Format: Cohort-based training sessions · Certification issued per participant · Curriculum customised to your product range and patient conditions · Ongoing clinical resource access included
03
Phase 03 · Systemic Advisory
Full operational redesign. New patient outcomes. A defensible licence.
The deepest engagement: Gil works with your clinical operations team to redesign the entire patient journey from prescription to year two. New intake SOPs, condition-specific protocol libraries, outcome tracking infrastructure, and regulatory documentation — the full architecture of a medical cannabis programme that retains patients, not just acquires them.
Scope: 3–6 month advisory engagement · Weekly sessions + written deliverables · Retention KPI framework and dashboard design · Regulatory documentation support
Where every engagement begins
The Business Audit Call — $500
90 minutes. Gil reviews your current patient journey, dropout patterns, and onboarding process. You receive a written Retention Assessment the same day — specific to your operation, with a proposed intervention roadmap. No retainer. No obligation beyond the call.
Book the Business Audit Call — $500
The Audit Call

Ninety minutes to know exactly what is costing you patients —
and exactly what fixes it.

This is not a discovery call. Not a sales conversation. It is a structured diagnostic — the same analytical process Gil has run across Israel's largest operators — applied to your specific operation. You will leave knowing more about your patient retention problem than most operators ever discover.

The Business Audit Call · Diagnostic Investment
What happens in 90 minutes — and what you receive same day.
$500
One time · Credited against Phase 1
During the call
→Structured intake covering your patient acquisition model, current onboarding process, dropout timing patterns, product range, and condition profile mix
→Identification of your primary retention failure point — the specific gap in your patient journey where most of your dropouts are occurring, and why
→Intervention mapping: which of the three programme phases applies to your situation, in what sequence, at what likely patient volume and timeline
→Honest assessment of what is realistic for your operation — Gil will tell you if the system isn't the right fit, and why
What you receive same day
✓Written Retention Assessment — a clinical document identifying your primary dropout mechanism, the specific patient journey gap responsible for it, and a proposed intervention framework with measurable retention KPIs
✓Implementation roadmap — phase-by-phase proposal scoped to your patient volume and operational structure. Specific enough to take to your clinical team or board, not a general recommendation
✓The $500 is credited in full against Phase 1 if you proceed. You are not paying for a pitch. You are paying for the diagnostic — and the diagnostic is worth having regardless of what you decide next.
Book the Business Audit Call — $500
Slot confirmed within 24 hours · Available internationally
Diagnostic guarantee. If the Written Retention Assessment doesn't give you a clearer picture of your dropout problem than anything your team has produced internally — tell me. I'll refund the call. That's not a legal clause. That's confidence in the diagnostic.
Who You're Working With

The person who built this system
was also the patient it was built for.

Gil Luxenbourg — Licensed Medical Cannabis Instructor, Israel MoH
Gil Luxenbourg
Licensed MoH Instructor
Patient #7 · Israel

In 1999, during military service, Crohn's disease took 37 kilograms from my body in three months. Conventional medicine had run out of options. Medical cannabis — rough, unstandardised, obtained entirely outside any official system — stopped the decline. I became Patient #7 in Israel. Not because I was an advocate. Because I had no other option.

What I found, as a patient, was a system that handed people a medicine they didn't understand, with no starting dose, no titration guidance, no way to distinguish a therapeutic response from a side effect. Most people gave up. I spent the next twenty years figuring out why — and building the infrastructure to fix it.

"The 4-to-34 month result wasn't produced by a product innovation. It was produced by closing a gap that the entire industry had decided was someone else's problem. It is not. It is the entire problem."
Credentials that belong in this conversation
◆Patient #7 in Israel — first to receive a Ministry of Health medical cannabis licence by direct application, without a court order. His 2004 application changed the administrative pathway for every patient who followed.
◆Licensed Medical Cannabis Instructor, Israel Ministry of Health, since 2008 — the first in the country. Not self-declared. Ministry-certified. The licence that makes him legally authorised to train your staff.
◆Architect of Israel's first patient education programme (2008) and first nurses education programme (2012) — the programmes that produced the 4→34 month result across Tikun Olam, BOL Pharma, Shibolet, and IMC.
◆Founder, Israel Medical Cannabis Association (2005) — the national patients' organisation that built the country's first structured advocacy and education infrastructure.
◆Government advisor: Israel, Czech Republic, Bulgaria — addressed the Czech Parliament in 2012; his input opened the Schengen zone to medical cannabis patients. The policy conversations he participated in shaped the regulatory frameworks your licences sit inside.
◆US Patent holder — US11346051B2, cold terpene-printing technology. Twenty years building this industry from every angle: patient, advocate, educator, inventor, manufacturer, government advisor.
The Honest Conversation

Things operators say
before they see the retention data.

"We already have a medical team handling patient education."
Your medical team prescribes. What Gil builds is clinical onboarding — the structured process that happens between prescription and the patient's first functional protocol. These are different functions. Prescribing physicians don't have the time or the tooling to do calibrated starting-dose work, week-by-week titration guidance, and outcome tracking with every patient. That gap is precisely where the dropout happens. Gil's system fills it without replacing or conflicting with your clinical team.
"We've invested in patient education already — videos, guides, a portal."
Educational content is not a clinical protocol. The distinction matters: content tells a patient what cannabis is. A protocol tells them exactly what to take tonight, how much, at what pace to increase, and what a therapeutic response looks like versus a side effect that requires adjustment. No video produces that. No portal produces that. The 4→34 month result was not produced by content. It was produced by written, personalised, clinically calibrated titration maps delivered before the patient took their first dose.
"Our dropout rate is high but it's an industry-wide problem — not specific to us."
It is industry-wide. That is the point. The operators who fix it first own a significant competitive advantage — in patient lifetime value, in word-of-mouth quality, in regulatory positioning, and in the retention metrics that are beginning to appear in licensing conversations. Industry-wide problems that have documented solutions are not problems to accept — they are opportunities to lead.
"What does full engagement cost? We need to budget for this."
The audit call is $500. The written assessment it produces gives you the specific intervention recommendation and a scoped proposal for Phase 1. Pricing for execution is scoped after the diagnostic — because the right answer depends on your patient volume, condition profile, staff structure, and how much of the system you want to build internally versus have Gil execute directly. You will not be asked to budget for something before you know what it is and what it will produce.
Quick Answers

What operators ask
before booking the call.

Yes. The audit call and Phase 1 patient work are conducted remotely and are available internationally. Phase 2 team training and Phase 3 systemic advisory can be delivered remotely or in person depending on scope and geography. Gil has advised governments in three countries and worked with operators internationally — location is not a constraint for the diagnostic or the early execution phases.

The diagnostic is valuable regardless of size — understanding your retention failure point costs the same whether you have 500 patients or 50,000. Phase 1 patient rescue scales from small clinic referrals to high-volume operator triage programmes. Phase 2 and 3 are better suited to operations with at least 500 active patients and a dedicated clinical or dispensary team. The audit call will tell you which phases apply and at what threshold.

Phase 1 results are typically measurable within 30–60 days of the first patient referrals — because you are comparing the retention trajectory of protocol-onboarded patients against your existing cohort in real time. The 4→34 month result was not a long-term study — it was an observed difference between two patient populations, visible within the first few months of parallel operation. The audit call will give you a realistic projection specific to your dropout timing patterns.

Yes. The $500 is credited in full against Phase 1 if you move forward within 60 days of the call. You are not paying a pitch fee. You are paying for the diagnostic — and the written Retention Assessment has standalone value whether or not you proceed to execution.

Yes. Gil's MoH-licensed instruction credential covers training for both clinical staff and non-clinical patient-facing staff — dispensary advisors, patient coordinators, intake personnel. The curriculum is layered by role: clinical staff receive pharmacological depth; patient-facing staff receive protocol delivery training. The 2012 nurses education programme he built was the first of its kind in Israel precisely because the gap existed across both clinical and non-clinical roles.

You already know
your dropout rate is too high.
Now you know there's a fix.

The Business Audit Call is 90 minutes. You leave with a written assessment of exactly what is costing you patients — and a specific roadmap to fix it. No retainer. No long-term commitment required to start.

Book the Business Audit Call — $500
Slot confirmed within 24 hours · International availability
Gil's work with patients → Cannabis Rescue Session  ·  Full background → gilluxenbourg.com